Fallacies in clinical cardiovascular trials

Heart

Volumn 95, Issue 17, 2009, Pages 1464-1468

  Swedberg, Karl ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIARRHYTHMIC AGENT; ATORVASTATIN; BENAZEPRIL; C REACTIVE PROTEIN; CAPTOPRIL; DIURETIC AGENT; ENALAPRIL; ENCAINIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MILRINONE; MORACIZINE; MOXONIDINE; PIPERANOMETOZINE; PLACEBO; ROSUVASTATIN; TELMISARTAN; TORCETRAPIB;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STABLE ANGINA PECTORIS; STROKE; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 69249102101     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.154542     Document Type: Review

References (22)

1. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. ▶ Recent large randomised study with effects on lipid values but failed effect on outcome.
2. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. ▶ Recent statin trial targeting elevated CRP concentrations and found effective, but mechanism for the effect was not clarified.
3. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive Creactive protein levels. Circulation 2001;103:1933-5.
4. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
5. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med 2008;359:2195-207.
6. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-59.
7. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61. ▶ Large neutral study where a statin failed to show an effect on outcomes in patients with heart failure.
8. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 2008;372:1231-9.
9. Bigger JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250- 8. ▶ Important trial demonstrating the relationship between ventricular arrhythmias, ejection fraction and prognosis.
10. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406-12. ▶ Landmark study where class I antiarrhythmic agents in responders increased mortality.
11. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339:1810-16. ▶ Large randomised study with two doses of an inotropic agent increased mortality in a dose dependent manner.
12. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38. ▶ Randomised trial where blood pressure reduction did not translate into reduction of strokes.
13. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7. ▶ Large, randomised trial with active control which could not confirm initial positive results in pilot trial.
14. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429- 35.
15. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136-9.
16. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361:1843-8.
17. Holmboe ES, Fiellin DA, Cusanelli E, et al. Perceptions of benefit and risk of patients undergoing first-time elective percutaneous coronary revascularization. J Gen Intern Med 2000;15:632-7.
18. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005;111:2906-12.
19. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-407. ▶ Important randomised trial which showed that the open artery concept was not completely clear.
20. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61. ▶ Meta-analysis which indicated problems with metal stents.
21. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48.
22. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.